Skip to main content
Top
Literature
3.
go back to reference Van Damme BJ, Fleuren GJ, Bakker WW et al (1978) Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 38:502–510PubMed Van Damme BJ, Fleuren GJ, Bakker WW et al (1978) Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 38:502–510PubMed
4.
5.
go back to reference Kerjaschki D, Farquhar M (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci 79:5557–5561PubMedCentralPubMedCrossRef Kerjaschki D, Farquhar M (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci 79:5557–5561PubMedCentralPubMedCrossRef
6.
go back to reference Debiec H, Guigonis V, Mougenot B et al (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346:2053–2060PubMedCrossRef Debiec H, Guigonis V, Mougenot B et al (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346:2053–2060PubMedCrossRef
8.
go back to reference Warwicker P, Goodship TH, Donne RL et al (1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53:836–844PubMedCrossRef Warwicker P, Goodship TH, Donne RL et al (1998) Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 53:836–844PubMedCrossRef
9.
go back to reference Dragon-Durey MA, Loirat C, Cloarec S et al (2005) Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555–563PubMedCrossRef Dragon-Durey MA, Loirat C, Cloarec S et al (2005) Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555–563PubMedCrossRef
10.
go back to reference Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181PubMedCrossRef Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181PubMedCrossRef
11.
13.
15.
go back to reference Clement LC, Avila-Casado C, Macé C et al (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17:117–122PubMedCentralPubMedCrossRef Clement LC, Avila-Casado C, Macé C et al (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17:117–122PubMedCentralPubMedCrossRef
16.
go back to reference Reiser J, Chapman H (2014) Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken. J Am Soc Nephrol(May) Reiser J, Chapman H (2014) Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken. J Am Soc Nephrol(May)
18.
go back to reference Stanescu HC, Arcos-Burgos M, Medlar A et al (2011) Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364:616–626PubMedCrossRef Stanescu HC, Arcos-Burgos M, Medlar A et al (2011) Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364:616–626PubMedCrossRef
19.
go back to reference De Abreu FB, Wells WA, Tsongalis GJ (2013) The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol 183:1075–1083PubMedCrossRef De Abreu FB, Wells WA, Tsongalis GJ (2013) The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol 183:1075–1083PubMedCrossRef
21.
go back to reference Schmid H, Boucherot A, Yasuda Y et al. (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993–300PubMedCrossRef Schmid H, Boucherot A, Yasuda Y et al. (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993–300PubMedCrossRef
22.
go back to reference Kretzler M, Cohen CD (2010) Integrative biology of renal disease: toward a holistic understanding of the kidney’s function and failure. Semin Nephrol 3:439–442CrossRef Kretzler M, Cohen CD (2010) Integrative biology of renal disease: toward a holistic understanding of the kidney’s function and failure. Semin Nephrol 3:439–442CrossRef
23.
go back to reference Couser WG (2012) Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 23:381–399PubMedCrossRef Couser WG (2012) Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 23:381–399PubMedCrossRef
Metadata
Title
Ten-year advances in immunopathology of glomerulonephritis: translated into patients’ care or lost in translation?
Authors
Pierre Ronco
Jürgen Floege
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2014
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-014-0437-5

Other articles of this Issue 4/2014

Seminars in Immunopathology 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.